On Friday, Following stocks ended their trade in “Red-Zone“: Golar LNG (USA) (NASDAQ:GLNG), Rowan Companies (NYSE:RDC), Incyte (NASDAQ:INCY), Aratana Therapeutics (NASDAQ:PETX)

Golar LNG Limited (USA) (NASDAQ:GLNG) and Rosneft oil corporation have reached a Memorandum of considerate that foresees assistance between the companies in the area of floating liquefaction (FLNG) and transportation of natural gas.

Under this MoU the companies will enter into planning to develop opportunities for the use of Golar’s GoFLNG services in Latin America and potentially other locations. The parties are targeting signing of two FLNG clangor agreements for projects within Rosneft’s portfolio.

Rosneft is the third largest gas producer in Russia. Rosneft gas production reached 42.1 bcm in 2013, while the recoverable natural gas reserves topped 6.5 tcm. The company target is to reach 100 bcm of yearly gas production by 2020.

Golar LNG Limited (USA) (NASDAQ:GLNG) shares picked down -1.59%, and closed at $34.05. The stock volatility for the week is 4.73%, while for the month remained 5.06%. The company holds consensus target price of $52.56.

If we consider EPS growth of the company, then the company indicated the following observations:

The company showed -0.50 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -129.30% and Annual EPS growth for the past 5 years is considered as -26.90%.

The mean recommendation of analysts for this stock is 1.70. (Where 1=Buy, 5=Sale).

Golar LNG Limited (USA) (GLNG) a midstream liquefied natural gas (LNG) company is engaged in the transportation, re-gasification and liquefaction, and trading of LNG. The company operates in two segments, Vessel Operations and Commodity Trading.

Rowan Companies PLC (NYSE:RDC), declared that its magazine report of drilling rig.

Rowan Reliance: As formerly indicated, rig commenced operations on February 1, 2015 in the U.S. Gulf of Mexico.

• Cecil Provine: Awarded a one-well conservatory estimated for 45-days with Fieldwood in the U.S. Gulf of Mexico at a day rate of $85,000, expected to originate mid-April 2015.

• Ralph Coffman: predictable to complete accessible well at the current day rate of $200,000 at the end of May 2015 as a substitute of the end of July 2015.
• Charles Rowan: Adjusted expected agreement period for the primary term to April 2015 from March 2015 at the existing day rate of $70,000.

Rowan Companies PLC (NYSE:RDC) decreased -1.59%, and closed at $18.62. The stock has price to sale ratio of 1.27, however, price to book ratio is 0.49. With recent decline, the year-to-date (YTD) performance reflected a -21.3% decline. During the past month the stock lose -24.55%, bringing three-month performance to -21.57% and six-month performance to -29.49%. The mean recommendation of analysts for this stock is 2.60. (where 1=Buy, 5=Sale).

Rowan Companies PLC (RDC) provides offshore oil and gas contract drilling services. It operates a fleet of 30 self-elevating mobile offshore jack-up drilling units, as well as 3 ultra-deepwater drill ships.

Incyte Corporation (NASDAQ:INCY) declared that Steven H. Stein, MD, has been selected Senior Vice President and Chief Medical Officer, effective directly. Dr. Stein was previously SVP, US Clinical Development & Medical Affairs at Novartis Oncology US, and he will be answerable for clinical and medical strategy and operations across Incyte’s widespread oncology collection.

He will join the administrative management team of Incyte, and report to Richard S. Levy, MD, Executive Vice President and Chief Drug Development Officer.

Incyte Corporation (NASDAQ:INCY) decreased -1.58%, and closed at $95.55, hitting new 52-week high of $99.00. The company holds the market capitalization of $16.41B. For the last twelve months, the stock was able to keep return on equity at 65.30%, while return on assets at –11.10%, in response to its return on investment at -0.80%. Its 20-day moving average gained 7.74%, above 50-day moving average of 17.05%, above 200-day moving average of 50.10% from the latest market price of $95.55. The mean recommendation of analysts for this stock is 1.60. (Where 1=Buy, 5=Sale).

Incyte Corporation (INCY), a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemi vera MF, and post-essential thrombocythemia MF.

Aratana Therapeutics Inc (NASDAQ:PETX) a pet therapeutics corporation alert on the licensing, development and commercialization of original biopharmaceutical goods for attendant animals, declared that it will present at theJefferies 2015 Animal Health Summit to be held March 26, 2015, at the Jefferies meeting Center in New York.

Aratana Therapeutics Inc (NASDAQ:PETX) fell -1.58%, and closed at $18.74.Its volatility for the week is 4.57%, while for the month it is 5.17%. The company has the market capitalization of $664.70 million. The company holds the book value per share of 6.58, whereas cash per share is 3.12. Price to book ratio remained 2.85, while price to sale ratio is 1084.11. Analysts mean recommendation for the stock is said to be 1.50 (where 1=Buy, 5=sale).

Aratana Therapeutics Inc (PETX), a development-stage biopharmaceutical company, focuses on the licensing, acquisition, development, and commercialization of biopharmaceutical products for cats, dogs, and other companion animals worldwide.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.